Abstract
A COVID-19 committee at Hunt Regional Medical Center reviewed the use of dapsone as an inflammasome competitor. The hospital then revalidated its effectiveness by reporting the findings of 44 (22 cases/22 controls) patients with acute respiratory distress syndrome (ARDS) treated with dapsone. All of 17 ARDS Onset patients who received standard COVID-19 treatment, including dapsone, did not die except one patient not taken dapsone after relapsed, whereas 8/20 patients who received standard COVID-19 treatment without dapsone died; the mortality rates were 5.9% and 40%, respectively. Dapsone treats and prevents SARS-CoV-2 ARDS. We confirmed that dapsone clinically treated the onset of ARDS by targeting SARS-CoV-2-activated inflammasomes.
Customizing rTMS treatment targeting for co-occurring alcohol use disorder and mild traumatic brain injury using multi-modal neuroimaging data as neurobiological markers
